Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism
Identifieur interne : 002A09 ( Istex/Corpus ); précédent : 002A08; suivant : 002A10Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism
Auteurs : Joong-Seok Kim ; Phil-Hyu Lee ; Kwang-Soo Lee ; Jeong-Wook Park ; Yeong-In Kim ; Yong-An Chung ; Sung-Hoon Kim ; Seung-Hyun Kim ; Juhan Kim ; Yun-Young Choi ; Hee-Tae KimSource :
- Movement Disorders [ 0885-3185 ] ; 2006-11.
English descriptors
Abstract
The purpose of our study was to prospectively evaluate cardiac [123I]metaiodobenzylguanidine (MIBG) uptake in patients with cerebrovascular disease (CVD) who develop clinical symptoms of vascular Parkinsonism (VP). A total of 19 consecutive patients who developed Parkinsonism during the course of their CVD were enrolled in the study; 16 age‐matched subjects, and 30 patients with Parkinson's disease (PD) were also evaluated with cardiac MIBG uptake. MIBG uptake was assessed using the ratio of the heart to the upper mediastinum (H/M) according to planar scintigraphic data. The mean H/M ratio was significantly higher in patients with VP than in those with PD (2.28 ± 0.41 vs. 1.27 ± 0.13; P < 0.001). MIBG uptake did not differ between VP and controls (2.46 ± 0.33; P > 0.05). Our findings suggest that myocardial postganglionic sympathetic dysfunction found in PD is absent in most patients with VP. MIBG single photon emission computed tomography imaging may be useful to help distinguish between PD and VP patients in clinical practice. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21112
Links to Exploration step
ISTEX:27ED9BC5C7E4E6F9E407ADEEA30E0CFCBF73DD19Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism</title><author><name sortKey="Kim, Joong Eok" sort="Kim, Joong Eok" uniqKey="Kim J" first="Joong-Seok" last="Kim">Joong-Seok Kim</name><affiliation><mods:affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Phil Yu" sort="Lee, Phil Yu" uniqKey="Lee P" first="Phil-Hyu" last="Lee">Phil-Hyu Lee</name><affiliation><mods:affiliation>Department of Neurology, Ajou University Medical College, Suwon, Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Kwang Oo" sort="Lee, Kwang Oo" uniqKey="Lee K" first="Kwang-Soo" last="Lee">Kwang-Soo Lee</name><affiliation><mods:affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Park, Jeong Ook" sort="Park, Jeong Ook" uniqKey="Park J" first="Jeong-Wook" last="Park">Jeong-Wook Park</name><affiliation><mods:affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Yeong N" sort="Kim, Yeong N" uniqKey="Kim Y" first="Yeong-In" last="Kim">Yeong-In Kim</name><affiliation><mods:affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Chung, Yong N" sort="Chung, Yong N" uniqKey="Chung Y" first="Yong-An" last="Chung">Yong-An Chung</name><affiliation><mods:affiliation>Department of Nuclear Medicine, The Catholic University of Korea, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Sung Oon" sort="Kim, Sung Oon" uniqKey="Kim S" first="Sung-Hoon" last="Kim">Sung-Hoon Kim</name><affiliation><mods:affiliation>Department of Nuclear Medicine, The Catholic University of Korea, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Seung Yun" sort="Kim, Seung Yun" uniqKey="Kim S" first="Seung-Hyun" last="Kim">Seung-Hyun Kim</name><affiliation><mods:affiliation>Department of Neurology, Hanyang University Medical College, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Juhan" sort="Kim, Juhan" uniqKey="Kim J" first="Juhan" last="Kim">Juhan Kim</name><affiliation><mods:affiliation>Department of Neurology, Hanyang University Medical College, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Choi, Yun Oung" sort="Choi, Yun Oung" uniqKey="Choi Y" first="Yun-Young" last="Choi">Yun-Young Choi</name><affiliation><mods:affiliation>Department of Nuclear Medicine, Hanyang University Medical College, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Hee Ae" sort="Kim, Hee Ae" uniqKey="Kim H" first="Hee-Tae" last="Kim">Hee-Tae Kim</name><affiliation><mods:affiliation>Department of Neurology, Hanyang University Medical College, Seoul, Korea</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:27ED9BC5C7E4E6F9E407ADEEA30E0CFCBF73DD19</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.21112</idno><idno type="url">https://api.istex.fr/document/27ED9BC5C7E4E6F9E407ADEEA30E0CFCBF73DD19/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002A09</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism</title><author><name sortKey="Kim, Joong Eok" sort="Kim, Joong Eok" uniqKey="Kim J" first="Joong-Seok" last="Kim">Joong-Seok Kim</name><affiliation><mods:affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Phil Yu" sort="Lee, Phil Yu" uniqKey="Lee P" first="Phil-Hyu" last="Lee">Phil-Hyu Lee</name><affiliation><mods:affiliation>Department of Neurology, Ajou University Medical College, Suwon, Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Kwang Oo" sort="Lee, Kwang Oo" uniqKey="Lee K" first="Kwang-Soo" last="Lee">Kwang-Soo Lee</name><affiliation><mods:affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Park, Jeong Ook" sort="Park, Jeong Ook" uniqKey="Park J" first="Jeong-Wook" last="Park">Jeong-Wook Park</name><affiliation><mods:affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Yeong N" sort="Kim, Yeong N" uniqKey="Kim Y" first="Yeong-In" last="Kim">Yeong-In Kim</name><affiliation><mods:affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Chung, Yong N" sort="Chung, Yong N" uniqKey="Chung Y" first="Yong-An" last="Chung">Yong-An Chung</name><affiliation><mods:affiliation>Department of Nuclear Medicine, The Catholic University of Korea, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Sung Oon" sort="Kim, Sung Oon" uniqKey="Kim S" first="Sung-Hoon" last="Kim">Sung-Hoon Kim</name><affiliation><mods:affiliation>Department of Nuclear Medicine, The Catholic University of Korea, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Seung Yun" sort="Kim, Seung Yun" uniqKey="Kim S" first="Seung-Hyun" last="Kim">Seung-Hyun Kim</name><affiliation><mods:affiliation>Department of Neurology, Hanyang University Medical College, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Juhan" sort="Kim, Juhan" uniqKey="Kim J" first="Juhan" last="Kim">Juhan Kim</name><affiliation><mods:affiliation>Department of Neurology, Hanyang University Medical College, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Choi, Yun Oung" sort="Choi, Yun Oung" uniqKey="Choi Y" first="Yun-Young" last="Choi">Yun-Young Choi</name><affiliation><mods:affiliation>Department of Nuclear Medicine, Hanyang University Medical College, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Hee Ae" sort="Kim, Hee Ae" uniqKey="Kim H" first="Hee-Tae" last="Kim">Hee-Tae Kim</name><affiliation><mods:affiliation>Department of Neurology, Hanyang University Medical College, Seoul, Korea</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-11">2006-11</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1990">1990</biblScope><biblScope unit="page" to="1994">1994</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">27ED9BC5C7E4E6F9E407ADEEA30E0CFCBF73DD19</idno><idno type="DOI">10.1002/mds.21112</idno><idno type="ArticleID">MDS21112</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>MIBG scintigraphy</term><term>Parkinson's disease</term><term>vascular Parkinsonism</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The purpose of our study was to prospectively evaluate cardiac [123I]metaiodobenzylguanidine (MIBG) uptake in patients with cerebrovascular disease (CVD) who develop clinical symptoms of vascular Parkinsonism (VP). A total of 19 consecutive patients who developed Parkinsonism during the course of their CVD were enrolled in the study; 16 age‐matched subjects, and 30 patients with Parkinson's disease (PD) were also evaluated with cardiac MIBG uptake. MIBG uptake was assessed using the ratio of the heart to the upper mediastinum (H/M) according to planar scintigraphic data. The mean H/M ratio was significantly higher in patients with VP than in those with PD (2.28 ± 0.41 vs. 1.27 ± 0.13; P < 0.001). MIBG uptake did not differ between VP and controls (2.46 ± 0.33; P > 0.05). Our findings suggest that myocardial postganglionic sympathetic dysfunction found in PD is absent in most patients with VP. MIBG single photon emission computed tomography imaging may be useful to help distinguish between PD and VP patients in clinical practice. © 2006 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Joong‐Seok Kim MD</name><affiliations><json:string>Department of Neurology, The Catholic University of Korea, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Phil‐Hyu Lee MD</name><affiliations><json:string>Department of Neurology, Ajou University Medical College, Suwon, Korea</json:string></affiliations></json:item><json:item><name>Kwang‐Soo Lee MD</name><affiliations><json:string>Department of Neurology, The Catholic University of Korea, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Jeong‐Wook Park MD</name><affiliations><json:string>Department of Neurology, The Catholic University of Korea, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Yeong‐In Kim MD</name><affiliations><json:string>Department of Neurology, The Catholic University of Korea, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Yong‐An Chung MD</name><affiliations><json:string>Department of Nuclear Medicine, The Catholic University of Korea, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Sung‐Hoon Kim MD</name><affiliations><json:string>Department of Nuclear Medicine, The Catholic University of Korea, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Seung‐Hyun Kim MD</name><affiliations><json:string>Department of Neurology, Hanyang University Medical College, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Juhan Kim MD</name><affiliations><json:string>Department of Neurology, Hanyang University Medical College, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Yun‐Young Choi MD</name><affiliations><json:string>Department of Nuclear Medicine, Hanyang University Medical College, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Hee‐Tae Kim MD</name><affiliations><json:string>Department of Neurology, Hanyang University Medical College, Seoul, Korea</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>vascular Parkinsonism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>MIBG scintigraphy</value></json:item></subject><language><json:string>eng</json:string></language><abstract>The purpose of our study was to prospectively evaluate cardiac [123I]metaiodobenzylguanidine (MIBG) uptake in patients with cerebrovascular disease (CVD) who develop clinical symptoms of vascular Parkinsonism (VP). A total of 19 consecutive patients who developed Parkinsonism during the course of their CVD were enrolled in the study; 16 age‐matched subjects, and 30 patients with Parkinson's disease (PD) were also evaluated with cardiac MIBG uptake. MIBG uptake was assessed using the ratio of the heart to the upper mediastinum (H/M) according to planar scintigraphic data. The mean H/M ratio was significantly higher in patients with VP than in those with PD (2.28 ± 0.41 vs. 1.27 ± 0.13; P > 0.001). MIBG uptake did not differ between VP and controls (2.46 ± 0.33; P > 0.05). Our findings suggest that myocardial postganglionic sympathetic dysfunction found in PD is absent in most patients with VP. MIBG single photon emission computed tomography imaging may be useful to help distinguish between PD and VP patients in clinical practice. © 2006 Movement Disorder Society</abstract><qualityIndicators><score>4.835</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1077</abstractCharCount><pdfWordCount>2807</pdfWordCount><pdfCharCount>19996</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>169</abstractWordCount></qualityIndicators><title>Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism</title><genre><json:string>Serial article</json:string></genre><host><volume>21</volume><pages><total>5</total><last>1994</last><first>1990</first></pages><issn><json:string>0885-3185</json:string></issn><issue>11</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2006</publicationDate><copyrightDate>2006</copyrightDate><doi><json:string>10.1002/mds.21112</json:string></doi><id>27ED9BC5C7E4E6F9E407ADEEA30E0CFCBF73DD19</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/27ED9BC5C7E4E6F9E407ADEEA30E0CFCBF73DD19/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/27ED9BC5C7E4E6F9E407ADEEA30E0CFCBF73DD19/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/27ED9BC5C7E4E6F9E407ADEEA30E0CFCBF73DD19/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2006</date></publicationStmt><notesStmt><note>Hanyang University - No. HY‐2005‐000‐0000‐1734;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism</title><author><persName><forename type="first">Joong‐Seok</forename><surname>Kim</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea</affiliation></author><author><persName><forename type="first">Phil‐Hyu</forename><surname>Lee</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Ajou University Medical College, Suwon, Korea</affiliation></author><author><persName><forename type="first">Kwang‐Soo</forename><surname>Lee</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea</affiliation></author><author><persName><forename type="first">Jeong‐Wook</forename><surname>Park</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea</affiliation></author><author><persName><forename type="first">Yeong‐In</forename><surname>Kim</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea</affiliation></author><author><persName><forename type="first">Yong‐An</forename><surname>Chung</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Nuclear Medicine, The Catholic University of Korea, Seoul, Korea</affiliation></author><author><persName><forename type="first">Sung‐Hoon</forename><surname>Kim</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Nuclear Medicine, The Catholic University of Korea, Seoul, Korea</affiliation></author><author><persName><forename type="first">Seung‐Hyun</forename><surname>Kim</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Hanyang University Medical College, Seoul, Korea</affiliation></author><author><persName><forename type="first">Juhan</forename><surname>Kim</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Hanyang University Medical College, Seoul, Korea</affiliation></author><author><persName><forename type="first">Yun‐Young</forename><surname>Choi</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Nuclear Medicine, Hanyang University Medical College, Seoul, Korea</affiliation></author><author><persName><forename type="first">Hee‐Tae</forename><surname>Kim</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Department of Neurology, Hanyang University Hospital, 17, Haengdang‐dong, Sungdong‐gu, Seoul, 133‐792, Korea</p></note><affiliation>Department of Neurology, Hanyang University Medical College, Seoul, Korea</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-11"></date><biblScope unit="vol">21</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1990">1990</biblScope><biblScope unit="page" to="1994">1994</biblScope></imprint></monogr><idno type="istex">27ED9BC5C7E4E6F9E407ADEEA30E0CFCBF73DD19</idno><idno type="DOI">10.1002/mds.21112</idno><idno type="ArticleID">MDS21112</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2006</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The purpose of our study was to prospectively evaluate cardiac [123I]metaiodobenzylguanidine (MIBG) uptake in patients with cerebrovascular disease (CVD) who develop clinical symptoms of vascular Parkinsonism (VP). A total of 19 consecutive patients who developed Parkinsonism during the course of their CVD were enrolled in the study; 16 age‐matched subjects, and 30 patients with Parkinson's disease (PD) were also evaluated with cardiac MIBG uptake. MIBG uptake was assessed using the ratio of the heart to the upper mediastinum (H/M) according to planar scintigraphic data. The mean H/M ratio was significantly higher in patients with VP than in those with PD (2.28 ± 0.41 vs. 1.27 ± 0.13; P < 0.001). MIBG uptake did not differ between VP and controls (2.46 ± 0.33; P > 0.05). Our findings suggest that myocardial postganglionic sympathetic dysfunction found in PD is absent in most patients with VP. MIBG single photon emission computed tomography imaging may be useful to help distinguish between PD and VP patients in clinical practice. © 2006 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>vascular Parkinsonism</term></item><item><term>MIBG scintigraphy</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2006-02-13">Received</change><change when="2006-06-03">Registration</change><change when="2006-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/27ED9BC5C7E4E6F9E407ADEEA30E0CFCBF73DD19/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="110"><doi origin="wiley" registered="yes">10.1002/mds.v21:11</doi><numberingGroup><numbering type="journalVolume" number="21">21</numbering><numbering type="journalIssue">11</numbering></numberingGroup><coverDate startDate="2006-11">November 2006</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="310" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21112</doi><idGroup><id type="unit" value="MDS21112"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2006 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2006-02-13"></event><event type="manuscriptRevised" date="2006-05-09"></event><event type="manuscriptAccepted" date="2006-06-03"></event><event type="publishedOnlineEarlyUnpaginated" date="2006-09-21"></event><event type="firstOnline" date="2006-09-21"></event><event type="publishedOnlineFinalForm" date="2006-11-08"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1990</numbering><numbering type="pageLast">1994</numbering></numberingGroup><correspondenceTo>Department of Neurology, Hanyang University Hospital, 17, Haengdang‐dong, Sungdong‐gu, Seoul, 133‐792, Korea</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21112.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="17"></count><count type="wordTotal" number="2795"></count></countGroup><titleGroup><title type="main" xml:lang="en">Cardiac [<sup>123</sup>I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism</title><title type="short" xml:lang="en">Cardiac MIBG Scintigraphy for Vascular Parkinsonism</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Joong‐Seok</givenNames><familyName>Kim</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Phil‐Hyu</givenNames><familyName>Lee</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Kwang‐Soo</givenNames><familyName>Lee</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Jeong‐Wook</givenNames><familyName>Park</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Yeong‐In</givenNames><familyName>Kim</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Yong‐An</givenNames><familyName>Chung</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Sung‐Hoon</givenNames><familyName>Kim</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Seung‐Hyun</givenNames><familyName>Kim</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Juhan</givenNames><familyName>Kim</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Yun‐Young</givenNames><familyName>Choi</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af4" corresponding="yes"><personName><givenNames>Hee‐Tae</givenNames><familyName>Kim</familyName><degrees>MD</degrees></personName><contactDetails><email>kimht@hanyang.ac.kr</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="KR" type="organization"><unparsedAffiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="KR" type="organization"><unparsedAffiliation>Department of Neurology, Ajou University Medical College, Suwon, Korea</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="KR" type="organization"><unparsedAffiliation>Department of Nuclear Medicine, The Catholic University of Korea, Seoul, Korea</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="KR" type="organization"><unparsedAffiliation>Department of Neurology, Hanyang University Medical College, Seoul, Korea</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="KR" type="organization"><unparsedAffiliation>Department of Nuclear Medicine, Hanyang University Medical College, Seoul, Korea</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">vascular Parkinsonism</keyword><keyword xml:id="kwd3">MIBG scintigraphy</keyword></keywordGroup><fundingInfo><fundingAgency>Hanyang University</fundingAgency><fundingNumber>HY‐2005‐000‐0000‐1734</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The purpose of our study was to prospectively evaluate cardiac [<sup>123</sup>I]metaiodobenzylguanidine (MIBG) uptake in patients with cerebrovascular disease (CVD) who develop clinical symptoms of vascular Parkinsonism (VP). A total of 19 consecutive patients who developed Parkinsonism during the course of their CVD were enrolled in the study; 16 age‐matched subjects, and 30 patients with Parkinson's disease (PD) were also evaluated with cardiac MIBG uptake. MIBG uptake was assessed using the ratio of the heart to the upper mediastinum (H/M) according to planar scintigraphic data. The mean H/M ratio was significantly higher in patients with VP than in those with PD (2.28 ± 0.41 vs. 1.27 ± 0.13; <i>P</i> < 0.001). MIBG uptake did not differ between VP and controls (2.46 ± 0.33; <i>P</i> > 0.05). Our findings suggest that myocardial postganglionic sympathetic dysfunction found in PD is absent in most patients with VP. MIBG single photon emission computed tomography imaging may be useful to help distinguish between PD and VP patients in clinical practice. © 2006 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Cardiac MIBG Scintigraphy for Vascular Parkinsonism</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Cardiac [</title></titleInfo><name type="personal"><namePart type="given">Joong‐Seok</namePart><namePart type="family">Kim</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Phil‐Hyu</namePart><namePart type="family">Lee</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Ajou University Medical College, Suwon, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kwang‐Soo</namePart><namePart type="family">Lee</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jeong‐Wook</namePart><namePart type="family">Park</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yeong‐In</namePart><namePart type="family">Kim</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yong‐An</namePart><namePart type="family">Chung</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Nuclear Medicine, The Catholic University of Korea, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sung‐Hoon</namePart><namePart type="family">Kim</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Nuclear Medicine, The Catholic University of Korea, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Seung‐Hyun</namePart><namePart type="family">Kim</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Hanyang University Medical College, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Juhan</namePart><namePart type="family">Kim</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Hanyang University Medical College, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yun‐Young</namePart><namePart type="family">Choi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Nuclear Medicine, Hanyang University Medical College, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hee‐Tae</namePart><namePart type="family">Kim</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Hanyang University Medical College, Seoul, Korea</affiliation><description>Correspondence: Department of Neurology, Hanyang University Hospital, 17, Haengdang‐dong, Sungdong‐gu, Seoul, 133‐792, Korea</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2006-11</dateIssued><dateCaptured encoding="w3cdtf">2006-02-13</dateCaptured><dateValid encoding="w3cdtf">2006-06-03</dateValid><copyrightDate encoding="w3cdtf">2006</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">2</extent><extent unit="references">17</extent><extent unit="words">2795</extent></physicalDescription><abstract lang="en">The purpose of our study was to prospectively evaluate cardiac [123I]metaiodobenzylguanidine (MIBG) uptake in patients with cerebrovascular disease (CVD) who develop clinical symptoms of vascular Parkinsonism (VP). A total of 19 consecutive patients who developed Parkinsonism during the course of their CVD were enrolled in the study; 16 age‐matched subjects, and 30 patients with Parkinson's disease (PD) were also evaluated with cardiac MIBG uptake. MIBG uptake was assessed using the ratio of the heart to the upper mediastinum (H/M) according to planar scintigraphic data. The mean H/M ratio was significantly higher in patients with VP than in those with PD (2.28 ± 0.41 vs. 1.27 ± 0.13; P < 0.001). MIBG uptake did not differ between VP and controls (2.46 ± 0.33; P > 0.05). Our findings suggest that myocardial postganglionic sympathetic dysfunction found in PD is absent in most patients with VP. MIBG single photon emission computed tomography imaging may be useful to help distinguish between PD and VP patients in clinical practice. © 2006 Movement Disorder Society</abstract><note type="funding">Hanyang University - No. HY‐2005‐000‐0000‐1734; </note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>vascular Parkinsonism</topic><topic>MIBG scintigraphy</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><detail type="issue"><caption>no.</caption><number>11</number></detail><extent unit="pages"><start>1990</start><end>1994</end><total>5</total></extent></part></relatedItem><identifier type="istex">27ED9BC5C7E4E6F9E407ADEEA30E0CFCBF73DD19</identifier><identifier type="DOI">10.1002/mds.21112</identifier><identifier type="ArticleID">MDS21112</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2006 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A09 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002A09 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:27ED9BC5C7E4E6F9E407ADEEA30E0CFCBF73DD19
|texte= Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism
}}
| This area was generated with Dilib version V0.6.23. |  |